A 90 minute COVID-19 test proves its accuracy

Service Engineering

Consumer DNA testing technology, re-engineered to diagnose COVID-19 quickly, has shown one hundred per cent specificity and ninety-four per cent sensitivity.

At the beginning of the pandemic, the consumer DNA testing device from DnaNudge was re-engineered to include a laboratory-free, rapid reverse transcription-polymerase chain reaction COVID-19 testing tool. The device efficacy has been confirmed, following Imperial College London's study.

“A 90 minute COVID-19 test proves its accuracy. “

During the research, three hundred and eighty-six patients and NHS staff were tested with the high-speed CovidNudge which can be carried out in cartridges smaller than a cell phone and doesn’t require a laboratory. No false positives and limited false negatives were developed by the Lab-in-Cartridge rapid testing system and are detailed in The Lancet Microbe.

The CovidNudge test, which is due to be rolled out nationally, is currently being used across eight London hospitals.

To conduct a test, a patient's nose swab sample is implanted into the device, which searches for signs of genetic material related to the SARS-CoV-2 virus. In contrast to the standard test that produces a result within twenty-four hours, a result will be obtained within ninety minutes.

The test is currently being developed for assessing Flu-B, Flu-A, COVID-19 and RSV simultaneously.

Lead author of the study from the Department of Infectious Disease, Imperial, Professor Graham Cooke, stated: “These results suggest the test, which can be performed at a patient’s bedside without the need to handle any sample material, has comparable accuracy to standard laboratory testing. Many tests involve a trade-off between speed and accuracy, but this test manages to achieve both. Developing an effective bedside test in under three months has been an incredible collaboration between teams of engineers, clinicians and virologists.”

Founder of the Institute of Biomedical Engineering at Imperial and CEO and Co-Founder of DnaNudge, Regius Professor Chris Toumazou, stated: “The DnaNudge test was developed as a lab-free, on-the-spot consumer service that can be delivered at scale, so we clearly believe it offers very significant potential in terms of mass population testing during the COVID-19 pandemic. The platform is well suited to testing in primary care and community settings with potential for use in non-healthcare settings such as care homes, schools, transport hubs, offices and to help bring the arts back, in theatres and venues. However, further studies of real world effectiveness in non-clinical settings would be required prior to widespread deployment.”

See all the latest jobs in Service Engineering
Return to news